Carlton Fleming

Carlton’s substantial experience includes the following representative matters:

• Akeso Biopharma in its US$5 billion collaboration and licensing agreement with Summit Therapeutics Inc.
• Atara Biotherapeutics, Inc. in its initial public offering and multiple follow-on equity offerings.
• Cornerstone OnDemand, Inc. in its US$1.4 billion acquisition of Saba Software.
• Cytokinetics, Incorporated in its US$138 million offering of senior notes, multiple follow-on equity offerings, and royalty financing transactions.
• DocuSign, Inc. in its:
  • US$303.0 million Series E financing;
  • US$723.7 million initial public offering;
  • US$443.3 million follow-on equity offering and concurrent offering US$575 million 0.5% convertible senior notes due 2023; and
  • US$188 million acquisition of Seal Software.
• Eiger BioPharmaceuticals, Inc. in multiple follow-on equity offerings.
• Kodiak Sciences Inc. in its:
  • US$312 million and US$645 million follow-on equity offerings; and
  • US$225 million royalty financing transaction.
• Quotient Technology Inc. in its proxy contest defense against Engaged Capital.
• Lyell Immunopharma, Inc. in its US$493 million Series C financing.
• MobileIron, Inc. in its US$100.0 million initial public offering.
• NGM Biopharmaceuticals, Inc. in its US$106.7 million initial public offering and US$143.8 million follow-on offering.
• Pliant Therapeutics, Inc. in its US$230.0 million and $287.5 million follow-on equity offerings.
• Prothena Corporation plc in its US$183.6 million follow-on equity offering.
• Rigel Pharmaceuticals, Inc. in multiple follow-on equity offerings.
• Talis Biomedical Corporation in its US$232.5 million initial public offering.
• Takeda Pharmaceutical Company Limited in its collaboration with and equity investment in Denali Therapeutics.
• Twilio Inc. in its US$1.8 billion public offering of Class A common stock and US$1.0 billion public offering of senior notes.
• Vaxcyte, Inc. in its US$287.5 million initial public offering.
• Vera Therapeutics, Inc. in its initial public offering.
• Zynga, Inc. in its US$527 million acquisition of NaturalMotion.

Some of the matters above were handled prior to joining Sidley.